IRIS International Inc. Stock Upgraded (IRIS)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- IRIS International (Nasdaq: IRIS) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Highlights from the ratings report include:
  • IRIS's revenue growth has slightly outpaced the industry average of 5.9%. Since the same quarter one year prior, revenues slightly increased by 2.5%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • IRIS has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 2.66, which clearly demonstrates the ability to cover short-term cash needs.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 452.0% when compared to the same quarter one year prior, rising from -$0.34 million to $1.21 million.
  • Net operating cash flow has significantly increased by 289.41% to $3.01 million when compared to the same quarter last year. In addition, IRIS INTERNATIONAL INC has also vastly surpassed the industry average cash flow growth rate of 13.55%.
  • The gross profit margin for IRIS INTERNATIONAL INC is rather high; currently it is at 58.30%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, IRIS's net profit margin of 3.90% significantly trails the industry average.

IRIS International, Inc. manufactures in vitro diagnostic (IVD) products for urinalysis and body fluids. The company has a P/E ratio of 335.5, equal to the average electronics industry P/E ratio and above the S&P 500 P/E ratio of 17.7. IRIS International has a market cap of $242.3 million and is part of the technology sector and electronics industry. Shares are up 109% year to date as of the close of trading on Tuesday.

You can view the full IRIS International Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

IRIS International Inc. Stock Downgraded (IRIS)

IRIS International Inc. Stock Downgraded (IRIS)

IRIS International Inc. Stock Upgraded (IRIS)

IRIS International Inc. Stock Upgraded (IRIS)

IRIS International Inc. Stock Downgraded (IRIS)

IRIS International Inc. Stock Downgraded (IRIS)

IRIS International Inc. Stock Upgraded (IRIS)

IRIS International Inc. Stock Upgraded (IRIS)